EA201591188A1 - Доставка глатирамера ацетата через слизистую оболочку - Google Patents

Доставка глатирамера ацетата через слизистую оболочку

Info

Publication number
EA201591188A1
EA201591188A1 EA201591188A EA201591188A EA201591188A1 EA 201591188 A1 EA201591188 A1 EA 201591188A1 EA 201591188 A EA201591188 A EA 201591188A EA 201591188 A EA201591188 A EA 201591188A EA 201591188 A1 EA201591188 A1 EA 201591188A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acetate
gletiramer
slighty
delivery
shell
Prior art date
Application number
EA201591188A
Other languages
English (en)
Inventor
Урсула Гайстер
Штефан Швайцер
Мартина Бюргер
Ральф Штефан
Геральд Хубер
Таня Прис
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201591188A1 publication Critical patent/EA201591188A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к пероральной таблетке, содержащей глатирамера ацетат в количестве от приблизительно 10 до приблизительно 60 мас.% и одно или несколько гелеобразующих веществ в общем количестве до приблизительно 90 мас.%. Настоящее изобретение также относится к способу доставки глатирамера ацетата через слизистую оболочку щечной области, и указанный способ содержит пероральное введение пероральной таблетки согласно любому из вариантов осуществления.
EA201591188A 2012-12-21 2013-12-20 Доставка глатирамера ацетата через слизистую оболочку EA201591188A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
EA201591188A1 true EA201591188A1 (ru) 2016-04-29

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591188A EA201591188A1 (ru) 2012-12-21 2013-12-20 Доставка глатирамера ацетата через слизистую оболочку

Country Status (15)

Country Link
US (1) US20160193276A1 (ru)
EP (1) EP2934492A4 (ru)
JP (1) JP2016503803A (ru)
KR (1) KR20150111918A (ru)
CN (1) CN104869983A (ru)
AU (1) AU2013361053A1 (ru)
BR (1) BR112015014095A2 (ru)
CA (1) CA2895359A1 (ru)
EA (1) EA201591188A1 (ru)
HK (2) HK1214134A1 (ru)
IL (1) IL239280A0 (ru)
MX (1) MX2015007678A (ru)
SG (1) SG11201504422XA (ru)
WO (1) WO2014100639A1 (ru)
ZA (1) ZA201505049B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3119413B1 (en) 2014-03-17 2021-05-12 Mapi Pharma Limited Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
CN108601737A (zh) * 2016-02-12 2018-09-28 特华制药株式会社 干法制粒物和含有该干法制粒物的固态制剂及它的制造方法
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120648D1 (de) * 2000-02-18 2006-07-27 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
MXPA04000209A (es) * 2001-07-10 2005-03-07 Teva Pharma Sistema de administracion para la administracion de droga de orden cero, bifasica de orden cero, ascendente o descendente.
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP2009515956A (ja) * 2005-11-22 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド テルミサルタンの医薬組成物
WO2007074472A2 (en) * 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
CN102887900B (zh) * 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Also Published As

Publication number Publication date
CN104869983A (zh) 2015-08-26
HK1214523A1 (zh) 2016-07-29
EP2934492A4 (en) 2016-08-17
AU2013361053A1 (en) 2015-07-30
WO2014100639A1 (en) 2014-06-26
JP2016503803A (ja) 2016-02-08
IL239280A0 (en) 2015-07-30
CA2895359A1 (en) 2014-06-26
MX2015007678A (es) 2015-09-07
SG11201504422XA (en) 2015-07-30
KR20150111918A (ko) 2015-10-06
US20160193276A1 (en) 2016-07-07
HK1214134A1 (zh) 2016-07-22
ZA201505049B (en) 2016-10-26
BR112015014095A2 (pt) 2017-07-11
EP2934492A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
MX2013001677A (es) Formulaciones estables de linaclotida.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
CY1116698T1 (el) Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EP3904502A3 (en) Compositions and methods
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
EP4233978A3 (en) Oral delivery of active drug substances
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
MX2010009851A (es) Oblea gingival.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
TN2012000574A1 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MX2013013204A (es) Sistema de suministro de farmaco.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MX2015007794A (es) Suministro transmucosal de acetato de glatiramer mediante parches orales.
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.